US APP wins FDA approval for generic 'Primacor'

01 June 2002 00:09  [Source: ICIS news]

HOUSTON (CNI)--American Pharmaceutical Partners (APP) said Friday it has received market approval from the US Food and Drug Administration (FDA) for its milrinone lactate injection for treatment of patients with acute low-output heart failure.

APP's generic version of milrinone is said by the company to be the equivalent of Sanofi-Synthelabo's Primacor, which had 2001 sales of some $186m (Euro198m).

Los Angeles, California-based APP said it has begun marketing milrinone in 10, 20 and 50 ml vials.

APP said that with the addition of milrinone, it now has five cardiovascular products on the market. APP had total sales in 2001 of $192m.

By: Joe Kamalick
+1 713 525 2653

AddThis Social Bookmark Button

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly